ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical"

  • Abstract Number: 943 • 2015 ACR/ARHP Annual Meeting

    Development of an Internationally Agreed Minimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical and Research Use

    Liza J. McCann1, Lucy R Wedderburn2, Clarissa Pilkington3, Adam M. Huber4, Angelo Ravelli5, Jamie Kirkham6, Paula Williamson6 and Michael W. Beresford7, 1Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 2Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, 3Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 4Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, 5Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy, 6Department of Biostatistics, University of Liverpool, MRC North West Hub for Trials Methodology Research, Liverpool, United Kingdom, 7Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare disease. International collaboration is essential for scrutiny of sufficient patient numbers. We aim to develop a core set…
  • Abstract Number: 950 • 2015 ACR/ARHP Annual Meeting

    In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients

    Jean-Pierre Pelletier1, Jean Pierre Raynauld2, André Beaulieu3, Louis Bessette4, Frédéric Morin5, Artur J Fernandes6, François Abram7, Marc Dorais8 and Johanne Martel-Pelletier9, 1Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Osteoarthritis Research Unit, CRCHUM, Montreal, Montreal, QC, Canada, 3Centre de rhumatologie St-Louis, St. Louis, QC, Canada, 4Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, 5Centre de Recherche Musculo-squelettique, Trois-Rivières, Trois-Rivières, QC, Canada, 6Centre de Recherche Musculo-squelettique, Trois-Rivières, 6Rheumatology Division, Sherbrooke, Sherbrooke, QC, Canada, 7Medical Imaging Research & Development, ArthroLab Inc, Montreal, QC, Canada, 8StatSciences Inc., Montreal, Canada, Montreal, QC, Canada, 9Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM),, Montreal, QC, Canada

    Background/Purpose: In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies using radiography to have a structure modifying effect, to…
  • Abstract Number: 1642 • 2015 ACR/ARHP Annual Meeting

    A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate Inadequate Responders with Rheumatoid Arthritis

    Roy Fleischmann1, Janet E. Pope2, Vanita Tongbram3, Derek Tang4, James Chung5, David Collier5, Shilpa Urs3, Kerigo Ndirangu3, George A. Wells6 and Ronald F. van Vollenhoven7, 1Rheumatology, Metroplex Clinical Research Center, Dallas, TX, 2University of Western Ontario, London, ON, Canada, 3ICON Plc., Morristown, NJ, 4Amgen, Inc., Thousand Oaks, CA, 5Amgen Inc., Thousand Oaks, CA, 6Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, 7Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Previously published rheumatoid arthritis (RA) trials in which TNFi-MTX and triple therapy (MTX + hydroxychloroquine + sulfasalazine) were included as treatment arms in MTX…
  • Abstract Number: 1654 • 2015 ACR/ARHP Annual Meeting

    A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis

    Roy Fleischmann1, Janet E. Pope2, Vanita Tongbram3, Derek Tang4, James Chung5, David Collier5, Shilpa Urs3, Kerigo Ndirangu3, George A. Wells6 and Ronald F. van Vollenhoven7, 1University of Texas Southwestern Medical Center, Dallas, TX, 2University of Western Ontario, London, ON, Canada, 3ICON Plc., Morristown, NJ, 4Amgen, Inc., Thousand Oaks, CA, 5Amgen Inc., Thousand Oaks, CA, 6Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, 7Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Several published randomized head-to-head trials in rheumatoid arthritis (RA) have compared TNFi-MTX with triple therapy (MTX + hydroxychloroquine + sulfasalazine) in MTX-naive patients (MTX-Ns)…
  • Abstract Number: 2693 • 2015 ACR/ARHP Annual Meeting

    Comparing Eight Year Clinical and Radiographic Outcome in Two Cohorts of Patients with Rheumatoid Arthritis

    Maria LE Andersson1, Kristina Forslind2 and Ingiäld Hafström3, 1R&D Centre Spenshult,Halmstad, Halmstad, Sweden, 2Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, 3Rheumatology Dept, Karoliska Institute, Stockholm, Sweden

    Background/Purpose: To compare patient and disease characteristics over the first 8 years of disease in a large inception cohort of early RA patients included 1992…
  • Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting

    Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort

    Kichul Ko1, Alana B. Levine2, Russell Griffin3, Olga Dvorkina4, Saira Sheikh5, Jinoos Yazdany6, Richard Furie7 and Cynthia Aranow8, 1Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3University of Alabama at Birmingham, Birmingham, AL, 4Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, 5University of North Carolina, Chapel Hill, NC, 6Rheumatology, University of California, San Francisco, San Francisco, CA, 7Division of Rheumatology, North Shore - LIJ Health System, New York, NY, 8Feinstein Institute for Medical Research, Mahasset, NY

    Background/Purpose:  Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
  • Abstract Number: 587 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics of Nonradiographic Axial Spondyloarthritis in Korea: A Comparison with Ankylosing Spondylitis

    Hyungjin Kim1, Hyemin Jeong1, Seulkee Lee1, Inyoung Kim1, Jiwon Hwang2, Jaejoon Lee1, Jinseok Kim3, Eun-Mi Koh4 and Hoon-Suk Cha5, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Department of Medicine,Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 31753-3, Ara-1 Dong, Jeju National University Hospital, Jeju, South Korea, 4Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: To evaluate the clinical characteristics and outcomes of nonradiographic axial spondyloarthritis (nr-axSpA) in Korean patients. Methods: A retrospective analysis evaluated 155 patients with nr-axSpA…
  • Abstract Number: 198 • 2014 ACR/ARHP Annual Meeting

    Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA

    Ishaan Swarup1, Ella Christoph1, Lisa A. Mandl2, Susan M. Goodman2 and Mark P. Figgie3, 1Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Orthopedics, Hospital for Special Surgery, New York, NY

    Background/Purpose :  Juvenile Idiopathic Arthritis (JIA) is a common rheumatologic disease in children that often persists into adulthood.  The hip joint is commonly involved, and…
  • Abstract Number: 74 • 2014 ACR/ARHP Annual Meeting

    Influence of the Polymorphism IL1ß (-511 A/C) and IL6 (- 174 G/C) on the Activity, Radiographic Damage and Clinical Forms of Patients with Psoriatic Arthritis (PSA)

    Tatiana Carranco1, Noelia Cubino2, Clara Cieza-Borrela3, Ismael Calero3, Maria Dolores Sanchez3, C. Hidalgo-Calleja4, Alba Quesada3, Andres Plata3, Agustin Diaz Alvarez3, Ricardo Usategui5, Rogelio Gonzalez5, C.a. Montilla-Morales4 and J. Del Pino-Montes4, 1Reumathology, HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, 2INTERNAL MEDICINE, HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, 3HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, 4University of Salamanca Hospital, Salamanca, Spain, 5IBSAL, SALAMANCA, Spain

    Background/Purpose: PSA is a chronic inflammatory disease associated to psoriasis which affects the joints, vertebrae and enthesis. Interleukin-1 is an inflammatory cytokine. A higher expression…
  • Abstract Number: L6 • 2014 ACR/ARHP Annual Meeting

    A PHASE 2, Randomized, Double-Blind Comparison of the Efficacy and Safety of PF-04171327 (1, 5, 10, 15 mg QD) Vs 5 and 10 Mg Prednisone QD or Placebo in Subjects with Rheumatoid Arthritis (RA) over 8 Weeks Followed By a 4-Week Taper of Study Drug

    Vibeke Strand1, Frank Buttgereit2, Dorothy McCabe3, Sheela Kolluri3, Brinda Tammara3, Ricardo Rojo3 and Judith Hey-Hadavi3,4, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Charité University Hospital, Berlin, Germany, 3Pfizer Inc, New York, NY, 4Pfizer Inc, NewYork, NY

    Background/Purpose: PF-04171327 is a dissociated agonist of the glucocorticoid receptor (DAGR), a selective high-affinity partial agonist of the GR with potent anti-inflammatory activity at exposures…
  • Abstract Number: 2904 • 2014 ACR/ARHP Annual Meeting

    Clinical and Radiological Features of Down’s Arthropathy

    Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland

    Background/Purpose The ‘Arthropathy of Down syndrome’ was first described in 1984. Three decades on we still have limited literature on the clinical & radiological features…
  • Abstract Number: 2404 • 2014 ACR/ARHP Annual Meeting

    RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-Term Response When Switched to SC MTX Monotherapy

    Anthony Hammond1 and Michael Batley2, 1Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Kent TN13 2JD, United Kingdom, 2Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom

    Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy, but many patients do not achieve adequate response to oral therapy for reasons of…
  • Abstract Number: 1420 • 2014 ACR/ARHP Annual Meeting

    Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR

    Salvador Loredo-Alanís1, David Vega-Morales2, Mario Garza-Elizondo1, Mario Garcia-Pompermayer3, Roberto Negrete-López1, Daniel Treviño-Montes1 and Diana Flores-Alvarado2, 1Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, 3Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterey, Mexico

    Background/Purpose The clinical evaluation of Rheumatoid arthritis (RA) is accomplished with compound indexes allowing better clinical decision. Clinical remission nowadays is an attainable target in…
  • Abstract Number: 1318 • 2014 ACR/ARHP Annual Meeting

    Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups

    Gulnara Mamyrova1, Lan Wu2, Adam Huber3, Ira N. Targoff4, Frederick W. Miller2 and Lisa G. Rider2, 1Rheumatology, George Washington University, Washington, DC, 2Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 3IWK Health Centre, Halifax, NS, Canada, 4Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: To evaluate features of JIIM clinical and Ab subgroups at illness onset.  Methods: Physician-completed questionnaires illness onset features were reviewed in 465 JIIM pts…
  • Abstract Number: 1193 • 2014 ACR/ARHP Annual Meeting

    Diagnostic value of Contrast-Enhanced MR-Angiography in diagnosing large Vessel Vasculitis

    Sabine Adler1, Marco Sprecher1, Harald Bonel2, Thorsten Klink2 and Peter M. Villiger3, 1Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, 2Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, 3Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland

    Background/Purpose Diagnosis of large-vessel vasculitis (LVV) remains difficult despite clinical and serological signs and symptoms. Detection by histology might be unavailable in exclusive thoracic or…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology